The Rare Neurodegenerative Disease Treatment Market To Be A Strong Contender To The Growth Of Healthcare Vertical From 2022 – 2031

The global rare neurodegenerative disease treatment market is projected to witness steady growth at a CAGR of 5%, reaching a valuation of over US$ 116 billion by 2030. However, the coronavirus outbreak is expected to have a marginally negative impact on the industry in the short term. Supply chain issues and dedication of healthcare facilities towards handling the unprecedented challenges of the pandemic are hindering market growth at present.

For detailed insights on enhancing your product footprint, request for a sample here –

On the other hand, increasing investments by market players towards drug development for the treatment of neurodegenerative diseases, and rising awareness among patients about varied treatment options, are major contributors to the growth of the market. Also, rise in medical tourism and investments towards modernization of healthcare infrastructure across developing countries in Asia Pacific are expected to benefit the rare neurodegenerative disease treatment market in the long term.

Key Takeaways from Rare Neurodegenerative Disease Treatment Market Study

  • North America is a prominent regional market, accounting for a major market share on the back of high healthcare expenditure and the presence of top pharmaceutical manufacturers in the region.
  • Hospital pharmacies are the leading channel of distribution for drugs associated with neurodegenerative diseases, driven by larger inventories.
  • Multiple sclerosis is the leading indication in the rare neurodegenerative disease treatment market, supported by growing awareness about the disease and rise in cases in recent years.
  • Sales of neuroprotective agents are essential for market revenue, with popularity supported by reduced side effects.
  • The COVID-19 pandemic is expected to have a moderate adverse impact on the global rare neurodegenerative disease treatment market in the short term.

For critical insights on this market, request for methodology here –

rare neurodegenerative disease treatment market market growth analysis

Key Segments of Rare Neurodegenerative Disease Treatment Market

Fact.MR’s study on the rare neurodegenerative disease treatment market offers information divided into four important segments — indication, drug class, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Indication Drug Class Distribution Channel Region
  • Multiple Sclerosis
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Acute Migraine
  • Autism
  • Narcolepsy
  • Amyotrophic Lateral Sclerosis (ALS)
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Spinal Muscular Atrophy
  • Tourette Syndrome
  • Huntington’s Disease
  • Others
  • Neurotransmitter Agents
  • Neuroprotective Agents
  • Biologics
  • Others
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

For in-depth competitive analysis, buy now –

Research on Product Development – Key to Market Growth

Leading players in the global rare neurodegenerative disease treatment market, such as Allergan plc, Bayer AG, GlaxoSmithKline, Johnson & Jonson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. are increasingly investing in capacity and geographical expansion and research into product development pertaining to neurodegenerative ailments. These are key factors that are likely to contribute to the growth of revenue and bolster product improvement in the competitive rare neurodegenerative disease treatment market landscape in the long term.

Read More Trending and Similar Reports from Fact.MR –

About Us:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.


US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates
Visit Our Website: